Phelan-McDermid syndrome, a genetic disorder closely tied to autism, may be far more common than scientists previously believed, according to a major new analysis. The study estimates that the condition could affect roughly 1 in 7,300 people, translating to more than 45,000 Americans.
The finding challenges the long-held view of Phelan-McDermid syndrome as an extremely rare disorder. Researchers warn that thousands of cases may remain hidden because genetic testing is often not performed, even when symptoms appear. That gap in diagnosis could delay care and leave families without answers.
Phelan-McDermid syndrome is caused by the loss or disruption of genetic material on chromosome 22, particularly the SHANK3 gene, which plays a key role in brain development and communication between neurons. The disorder is characterized by developmental delays, intellectual disability, absent or delayed speech, and autism-like behaviors. It is one of the most consistently identified genetic causes of autism spectrum disorder.
The new estimate of 1 in 7,300 is significantly higher than earlier figures, which often ranged from 1 in 30,000 to 1 in 50,000. The analysis suggests that the true prevalence may have been underestimated because many individuals with the condition never receive a genetic diagnosis. Without testing, clinicians may attribute symptoms to other developmental conditions or autism alone.
Researchers emphasize that broader access to genetic testing is essential. Early diagnosis can help families connect with specialized care, including speech therapy, behavioral interventions, and developmental support. It also allows patients to enroll in clinical trials for targeted treatments that are now moving forward.
Several experimental therapies aimed at addressing the underlying genetic cause of Phelan-McDermid syndrome are in development. These include approaches designed to restore SHANK3 function or compensate for its loss. As these treatments advance into clinical trials, identifying eligible patients becomes increasingly urgent. A larger, previously unrecognized patient population could accelerate research and improve trial recruitment.
The analysis also highlights the role of autism-linked genetic disorders in the broader understanding of neurodevelopmental conditions. While autism itself is highly heterogeneous, rare genetic syndromes like Phelan-McDermid offer a window into specific biological pathways. Studying these pathways may lead to treatments that benefit not only those with the syndrome but also others with related autism subtypes.
For families, the findings underscore the value of genetic evaluation when a child shows signs of developmental delay, especially if accompanied by low muscle tone, feeding difficulties, or absent speech. The researchers caution that their estimate is based on statistical modeling and may be refined as more data become available. Still, the message is clear: Phelan-McDermid syndrome is not as rare as once thought, and many people living with it may not know they have it.
As targeted therapies progress, the push for earlier and wider genetic testing could transform the landscape of care. The study calls for increased awareness among clinicians and the public, arguing that closing the diagnostic gap is a necessary step toward ensuring that everyone affected receives timely support and access to emerging treatments.
10
